BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rivfloza (Nedosiran) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rivfloza (Nedosiran)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04042402-911@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Rivfloza (Nedosiran): Phase 3 readout est. (NCT04042402)
DESCRIPTION:Rivfloza (Nedosiran)\, phase 3\, Primary Hyperoxaluria Type 1.\
 nStudy: Long Term Extension Study in Patients With Primary Hyperoxaluria\n
 Estimated primary completion: 1 April 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nedosiran#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04042402
URL:https://assetmemo.bio/drug/nedosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04580420-911@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Rivfloza (Nedosiran): Phase 2 readout est. (NCT04580420)
DESCRIPTION:Rivfloza (Nedosiran)\, phase 2\, Chronic Kidney Disease.\nStudy
 : Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD\nEstimated p
 rimary completion: 30 December 2031. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nedosiran#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04580420
URL:https://assetmemo.bio/drug/nedosiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
